Concentration and integrity indexes of urine cell-free DNA as promising biomarkers for early lung cancer diagnosis
Abstract
Aim: To explore the role of urine cell-free DNA (ucfDNA) concentration and integrity indexes as potential biomarkers for lung cancer diagnosis. Materials & methods: Quantitative real-time PCR targeting Arthrobacter luteus (ALU) repeats at three size fragments (ALU-60, 115 and 247 bp) was performed in 55 lung cancer patients and 35 healthy individuals. Results: ucfDNA concentration and integrity indexes were significantly higher in lung cancer patients than in healthy controls. The area under the receiver operating characteristic curve for differentiating patients with stage I/II from healthy controls by ALU fragments concentration were 0.856, 0.909 and 0.932, respectively. In addition, the ucfDNA integrity indexes in patients with lymph node metastasis were significantly higher than in patients with non-metastatic. Conclusion: ucfDNA concentration and integrity indexes could serve as promising biomarkers for lung cancer diagnosis.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). • Introduces the status report on the global burden of cancer in 2018, of which, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death.
- 2. . Clinical practice. the solitary pulmonary nodule. N. Engl. J. Med. 348(25), 2535–2542 (2003).
- 3. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer 47(1), 9–15 (2005).
- 4. Results of initial low-dose computed tomographic screening for lung cancer. N. Engl. J. Med. 368(21), 1980–1991 (2013).
- 5. . Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76(2), 138–143 (2012).
- 6. The role of TPS and TPA in the diagnostics of distant metastases. Anticancer Res. 36(2), 773–777 (2016).
- 7. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer. Eur. J. Surg. Oncol. 42(12), 1772–1779 (2016).
- 8. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23(7), 1420–1430 (2005). • Describes circulating tumor cells could be used as a novel prognostic biomarker for diagnosed metastatic breast cancer.
- 9. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 18(21), 5972–5982 (2012).
- 10. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br. J. Cancer 111(8), 1482–1489 (2014). • Describes circulating cell-free DNA (cfDNA) in serum as a promising biomarker for diagnosis and prognostic prediction of colorectal cancer.
- 11. . The biology and function of exosomes in cancer. J. Clin. Invest. 126(4), 1208–1215 (2016).
- 12. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17(1), 89–97 (1998).
- 13. . Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284(5756), 555–556 (1980).
- 14. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J. Clin. Oncol. 24(26), 4270–4276 (2006). • Describes serum cfDNA integrity as a biomarker for prediction of breast tumor progression.
- 15. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur. Respir. J. 46(6), 1773–1780 (2015).
- 16. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 52(6), 1062–1069 (2006). •• Evaluates serum cfDNA integrity as a potential biomarker for differentiating colorectal cancer or periampullary cancer from healthy individuals.
- 17. Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA. BMC Cancer 16(1), 943 (2016).
- 18. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J. Urol. 181(1), 363–371 (2009). •• Evaluates the diagnostic value of cfDNA integrity in patients with testicular germ cell cancer.
- 19. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 27(8), 415–421 (2008).
- 20. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J. Thorac. Oncol. 11(10), 1690–1700 (2016).
- 21. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncol. Rep. 18(2), 405–409 (2007).
- 22. Removal of high-molecular-weight DNA by carboxylated magnetic beads enhances the detection of mutated K-ras DNA in urine. Ann. NY Acad. Sci. 1137(1), 82–91 (2008). •• Describes mutated K-ras gene can be detected in urine DNA.
- 23. Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA. Cancer Biomark. 14(5), 295–302 (2014).
- 24. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J. Urol. 179(2), 508–511 (2008).
- 25. Initial sequencing and analysis of the human genome. Nature 409(6822), 860–921 (2001).
- 26. Insertion and/or deletion of many repeated DNA sequences in human and higher ape evolution. Proc. Natl Acad. Sci. 83(11), 3875–3879 (1986).
- 27. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin. Chem. 46(1), 1078–1084 (2000). •• Describes a new approach for detecting specific genomic DNA sequences in urine.
- 28. Circulating nucleic acids and apoptosis. Ann. NY Acad. Sci. 945(1), 239–249 (2001).
- 29. . Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study. Gene 590(1), 142–148 (2016).